Clinical trials: Lung Neoplasms/Diagnosis
Non-small Cell Lung Cancer, Lung Cancer
3D Virtual Resection for Predicting Lung Function in VATS
This study aims to validate a novel preoperative assessment strategy using three-dimensional (3-D) computed tomography (CT) reconstruction and virtual resection simulation.
- Conditions
- Non-small Cell Lung Cancer, Lung Cancer, Lung Neoplasms
- Trial name
- NCT07436598
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Lung Cancer, Tracheal Neoplasm
Airway and/or Pulmonary Vessels Transplantation
First study (BRONC-ART) The purpose of this prospective study is to evaluate the 90-day morbidity and mortality rates of bronchial transplantation using cryopreserved aortic allograft in proximal lung cancer surgery.
- Conditions
- Lung Cancer, Tracheal Neoplasm, Tracheal Stenosis
- Trial name
- TRACHBRONCAR (NCT01331863)
- Testing
- Airway and/or pulmonary Vessels Transplantation
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lung Cancer
Salivary Biomarkers for Non-small Cell Lung Cancer Detection
The investigators plan to recruit patients for a prospective study in patients in need of evaluation for lung lesions suspicious for cancer.
- Trial name
- NCT02294578
- Where
- 2 sites in United States
- Volunteers
- 166 people
- Sponsor
- PeriRx
Non Small Cell Lung Cancer
Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer
The purpose of this study is to evaluate whether the gemcitabine/vinorelbine combination versus the gemcitabine/docetaxel combination as first line treatment, offers a survival advantage in patients with locally…
- Trial name
- NCT00441740
- Testing
- Vinorelbine, Gemcitabine, Docetaxel
- Where
- 9 sites in Greece
- Volunteers
- 419 people
- Sponsor
- Hellenic Oncology Research Group
Non-Small Cell Lung Cancer
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of…
- Trial name
- NCT06496490
- Testing
- TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection
- Where
- 25 sites in China
- Volunteers
- 270 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
This phase II trial tests how well defactinib and avutometinib in combination with nivolumab works in treating patients with LKB1-mutant non-small cell lung cancer that has not responded (refractory) to an anti-PD1 treatment and…
- Conditions
- Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT06495125
- Testing
- Avutometinib, Biopsy, Biospecimen Collection
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Emory University
Non-small Cell Lung Cancer
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
- Trial name
- NAUTIKA1 (NCT04302025)
- Testing
- Alectinib, Entrectinib, Vemurafenib
- Where
- 38 sites in United States
- Volunteers
- 99 people
- Sponsor
- Genentech, Inc.
Venous Thromboembolism, Brain Tumors
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
In patients with malignant glioma, to determine the efficacy of prophylaxis with LMWH (dalteparin) compared to placebo, both commenced beyond the immediate postoperative period, for the prevention of VTE.
- Trial name
- NCT00135876
- Testing
- dalteparin
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 512 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Non-Small Cell Lung Cancer
Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC
A single arm, open-label phase II is appropriate to evaluate the efficacy and safety of dose - dense combination of paclitaxel with cisplatin supported by pegfilgrastim for neo-adjuvant chemotherapy in this patient population.
- Trial name
- NCT00291850
- Testing
- Paclitaxel, Cisplatin, Pegfilgrastim
- Where
- 5 sites in Austria, Hungary and 1 more
- Volunteers
- 50 people
- Sponsor
- Central European Cooperative Oncology Group
Breast Cancer, Colon Cancer
Physician Use of Non-English Language Skills in Cancer Care
The purpose of this study is to test a method for analyzing interactions between patients and doctors, the Roter Interaction Analysis System (RIAS).
- Conditions
- Breast Cancer, Colon Cancer, Lung Cancer
- Trial name
- NCT02726360
- Testing
- survey, Audio record
- Where
- 5 sites in United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Exercise Rehabilitation in Veteran Cancer Survivors
Exercise rehabilitation has the potential as a non-pharmacological approach to reduce persistent neuropathic pain in Veterans with lung cancer.
- Trial name
- NCT03621813
- Testing
- Exercise Rehabilitation, Control
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- VA Office of Research and Development
Non-small Cell Lung Cancer (NSCLC)
WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC
The aim of this trial is to evaluate the safety of WX-0593 combined with concurrent chemoradiotherapy in unresectable, locally advanced non-small cell lung cancer (NSCLC) with activating mutation of ALK or ROS1.
- Trial name
- NCT05351320
- Testing
- WX-0593 Tablets, chemotherapy, Thoracic Radiation Therapy（TRT）
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jinming Yu
Advanced Solid Tumor, Non Small Cell Lung Cancer
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
A Phase 1b/2, open-label, multicenter study to determine the recommended phase 2 (RP2D) of ABT-101in solid tumor and to explore antitumor activities of ABT-101 in patients with HER 2 mutated non-small cell lung cancer (NSCLC)
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer, HER2 Mutations
- Trial name
- NCT05532696
- Testing
- ABT-101
- Where
- 5 sites in Taiwan
- Volunteers
- 61 people
- Sponsor
- Anbogen Therapeutics, Inc.
NSCLC, Stage IV
Early Response Evaluation in NSCLC Patients Treated With Immunotherapy
A pilot study with biomarker exploration.50 patients with stage IV non-small cell lung cancer (NSCLC) that are eligible for treatment with nivolumab.
- Trial name
- NCT04082988
- Testing
- 18F-FDG PET-CT
- Where
- 2 sites in Netherlands
- Volunteers
- 9 people
- Sponsor
- The Netherlands Cancer Institute
Advanced Solid Tumor, Breast Cancer
A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer
The study will evaluate the pharmacokinetics (PK) and safety of a single intravenous (IV) dose of 0.3 mg/kg MB1707 in patients with advanced cancers.
- Conditions
- Advanced Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer, Ovary Cancer
- Trial name
- NCT05465590
- Testing
- MB1707
- Sponsor
- Mainline Biosciences, Inc.
Esophageal Carcinoma, Lung Carcinoma
Yoga Program for Improving the Quality of Life in Couples Coping With Cancer
This clinical trial seeks to learn if a yoga program can improve physical performance, quality of life and symptom burden in cancer patients who are undergoing radiation therapy, and their partners.
- Conditions
- Esophageal Carcinoma, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04607590
- Testing
- Best Practice, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
the Quality of Life Assessment of Lung Cancer Patients in China
The goal of this study is assess the quality of life of advanced non-small cell lung cancer (NSCLC) patients who are undergoing first-line chemotherapy, analyze the current status and tendency of quality of life (QOL).
- Trial name
- NCT01914120
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Sun Yat-sen University
Metastatic Pulmonary Nodules
Comparative Evaluation of MRI and MDCT for the Detection of Metastic Pulmonary Nodules
The purpose of this study is to apply the techniques of dynamic MRI imaging enhancement to research participants with one or more pulmonary nodule to determine if meaningful information about the nature of the nodule can be…
- Trial name
- NCT00751920
- Testing
- Enhanced MRI Scan
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- The Hospital for Sick Children
Non Small Cell Lung Cancer
Risk Factors of Medistinal Metastasis in Endoscopic Staging of Lung Cancer
The purpose of this study is to investigate risk factors for mediastinal lymph node metastasis in potentially operable non-small cell lung cancer in order to find indications for endoscopic mediastinal staging.
- Trial name
- NCT02991924
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- National Cancer Center, Korea
Unspecified Adult Solid Tumor, Protocol Specific
A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors
The purpose of this study is to determine the Maximum Tolerated Dose and the Dose-Limiting Toxicity of the drug to further evaluate safety and antitumor activity.
- Trial name
- NCT01631279
- Testing
- PR610
- Where
- 6 sites in United States, New Zealand
- Volunteers
- 33 people
- Sponsor
- Proacta, Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.